Live price temporarily unavailable.
Biofrontera (BFRI) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $18.8M | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Growth (year over year) | — | +27.9% | +19.0% | +18.8% | +9.5% | +11.7% |
| Operating income | −$9.61M | −$25.2M | −$18.6M | −$22.7M | −$17.2M | −$11.3M |
| Operating margin | −51.0% | −104.6% | −64.8% | −66.6% | −46.1% | −27.2% |
| Net income | −$11.0M | −$37.7M | −$640.0K | −$20.1M | −$17.8M | −$10.5M |
| Net margin | −58.3% | −156.5% | −2.2% | −59.1% | −47.6% | −25.3% |
| EPS (diluted) | −$191792.00 | −$1712.00 | −$0.61 | −$13.02 | −$3.22 | −$1.04 |
| Balance sheet | ||||||
| Cash and equivalents | $8.08M | $24.5M | $17.2M | $1.34M | $5.91M | $6.39M |
| Total assets | $24.1M | $53.2M | $50.9M | $27.9M | $22.1M | $28.6M |
| Total liabilities | $18.3M | $41.9M | $27.0M | $23.1M | $17.7M | $18.1M |
| Shareholders' equity | $5.83M | $11.3M | $23.9M | $4.79M | $4.43M | $10.5M |
| Cash flow | ||||||
| Operating cash flow | −$12.4M | −$26.7M | −$16.2M | −$24.9M | −$10.3M | −$13.4M |
| Capital expenditure | — | — | $38.0K | $5.00K | $10.0K | $2.00K |
| Free cash flow | — | — | −$16.2M | −$24.9M | −$10.3M | −$13.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.01M | $12.6M | $8.59M | $9.03M | $6.99M | $17.1M | $10.1M | $12.0M |
| Growth (year over year) | +1.3% | +18.5% | +8.5% | +15.2% | −22.5% | +36.2% | +17.4% | +32.9% |
| Operating income | −$4.96M | −$1.71M | −$4.55M | −$5.08M | −$6.28M | $4.56M | −$4.32M | −$524.0K |
| Operating margin | −55.0% | −13.6% | −52.9% | −56.2% | −89.8% | 26.6% | −42.8% | −4.4% |
| Net income | −$5.67M | −$1.40M | −$4.20M | −$5.32M | −$6.65M | $5.64M | −$4.75M | −$604.0K |
| Net margin | −62.9% | −11.1% | −48.9% | −59.0% | −95.1% | 33.0% | −47.1% | −5.0% |
| EPS (diluted) | −$0.98 | $0.69 | −$0.47 | −$0.57 | −$0.62 | $0.62 | −$0.41 | −$0.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $2.87M | $5.91M | $1.78M | $7.24M | $3.42M | $6.39M | $6.32M | $4.66M |
| Total assets | $18.5M | $22.1M | $16.6M | $20.1M | $15.4M | $28.6M | $24.8M | $24.1M |
| Total liabilities | $13.0M | $17.7M | $16.1M | $24.8M | $18.0M | $18.1M | $18.7M | $18.1M |
| Shareholders' equity | $5.53M | $4.43M | $469.0K | −$4.67M | −$2.58M | $10.5M | $6.07M | $5.96M |
| Cash flow | ||||||||
| Operating cash flow | −$1.21M | −$1.02M | −$4.12M | −$3.04M | −$3.82M | −$2.38M | −$70.0K | −$1.66M |
| Capital expenditure | $0 | $1.00K | $3.00K | $1.00K | −$1.00K | −$1.00K | $5.00K | $0 |
| Free cash flow | −$1.21M | −$1.02M | −$4.12M | −$3.05M | −$3.82M | −$2.38M | −$75.0K | −$1.66M |
From Biofrontera's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Biofrontera in our feed yet.